Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892450 · ClinicalTrials.gov registry record · NA
Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00892450 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 12 participants.
The verdict
NCT00892450, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate the cognitive (thinking, memory, knowledge, intelligence) side effects of two medications commonly used to treat overactive bladder (OAB) symptoms in veteran patients with Parkinson's disease (PD) seen at the Philadelphia PADRECC.
Interventions
- DRUG Oxybutynin and darifenacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892450
The ClinicalTrials.gov registry entry for NCT00892450 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxybutynin and darifenacin is the first listed.
NCT00892450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00892450 about?
NCT00892450 is a clinical study titled "Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease". The purpose of this research study is to investigate the cognitive (thinking, memory, knowledge, intelligence) side effects of two medications commonly used to treat overactive bladder (OAB) symptoms in veteran patients with Parkinson's disease (PD) seen at the Philadelphia PADRECC.
What is the current status of trial NCT00892450?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2009-05. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00892450?
The interventions under investigation include: Oxybutynin and darifenacin (DRUG).
Who is sponsoring clinical trial NCT00892450?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.